Hormone receptor-positive (HR+) breast cancer represents a significant portion of breast cancer diagnoses and has seen improvements in treatment outcomes with endocrine therapies. Despite these advances, both de novo and acquired resistance to these therapies remain critical challenges, particularly in metastatic settings. Ribociclib, a CDK4/6 inhibitor, has emerged as a standard treatment for advanced HR+ breast cancer; however, primary and acquired resistance to this drug is still observed. By analyzing Ribociclib's effects on immune cell infiltration and cellular senescence in HR+ breast cancer, its potential to enhance treatment outcomes can be assessed. This project is expected to provide valuable data for future clinical trials and contribute to developing novel combination therapies, ultimately advancing treatment strategies and improving outcomes for HR+ breast cancer patients. 

By testing the ability of CDK4/6 inhibitors to enhance sensitivity to first-line therapies and overcome resistance to immunotherapies or senescence-targeting therapies in advanced HR+ breast cancer, this research has the potential to significantly improve treatment strategies and patient outcomes.